Neogap appoints new Chief Medical Officer
Neogap Therapeutics, a biotech company focused on developing personalised cancer immunotherapy, announced today the appointment of Dr. Hanjing Xie as its new Chief Medical Officer (CMO), starting from 21 March. Dr. Xie will oversee Neogap's clinical development programs and pipeline and provide medical oversight for the company's first-in-human study. Dr. Xie is a highly experienced associate professor and senior consultant in oncology with diverse expertise from the pharmaceutical industry and university hospitals.Neogap Therapeutics recently received CTA approval for phase I/IIa clinical